Alfred H Schinkel

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Topics

Cancer Stem Cells

Signaling Pathway

Top Venues

Molecular pharmaceutics

Pharmaceuticals (Basel, Switzerland)

International journal of cancer

British journal of pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Nancy H C Loos, Margarida L F Martins, Jamie Rijmers, Daniëlle de Jong, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. Molecular pharmaceutics 21 (4) (2024)
Nancy H C Loos, Margarida L F Martins, Jamie Rijmers, Daniëlle de Jong, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. Molecular pharmaceutics 21 (4) (2024)
Nancy H C Loos, Margarida L F Martins, Jamie Rijmers, Daniëlle de Jong, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. Molecular pharmaceutics (2024)
Nancy H C Loos, Margarida L F Martins, Jamie Rijmers, Daniëlle de Jong, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. Molecular pharmaceutics 21 (4) (2024)
Nancy H C Loos, Margarida L F Martins, Daniëlle de Jong, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice. Molecular pharmaceutics (2023)
Jing Wang, M Merve Susam, Changpei Gan, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure. Pharmaceuticals (Basel, Switzerland) 15 (9) (2022)
Nancy H C Loos, Jos H Beijnen, Alfred H Schinkel
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism? International journal of molecular sciences 23 (17) (2022)
David Damoiseaux, Wenlong Li, Alejandra Martínez-Chávez, Jos H Beijnen, Alfred H Schinkel, Alwin D R Huitema, Thomas P C Dorlo
Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. Pharmaceuticals (Basel, Switzerland) 15 (7) (2022)
Wenlong Li, Rolf W Sparidans, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics 13 (11) (2021)
Yaogeng Wang, Rolf W Sparidans, Sander Potters, Rahime Şentürk, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals (Basel, Switzerland) 14 (11) (2021)
Wenlong Li, Rolf W Sparidans, Margarida L F Martins, Mujtaba El-Lari, Maria C Lebre, Olaf van Tellingen, Jos H Beijnen, Alfred H Schinkel
ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. Molecular cancer therapeutics 20 (6) (2021)
Margarida L F Martins, Nancy H C Loos, Sümeyra Mucuk, Danielle de Jong, Maria C Lebre, Hilde Rosing, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular pharmaceutics 18 (12) (2021)
Yaogeng Wang, Rolf W Sparidans, Wenlong Li, Maria C Lebre, Jos H Beijnen, Alfred H Schinkel
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British journal of pharmacology 177 (13) (2020)
Johannes J M Rood, Amer Jamalpoor, Stéphanie van Hoppe, Matthijs J van Haren, Roeland E Wasmann, Manoe J Janssen, Alfred H Schinkel, Rosalinde Masereeuw, Jos H Beijnen, Rolf W Sparidans
Extrahepatic metabolism of ibrutinib. Investigational new drugs 39 (1) (2020)
Wenlong Li, Matthijs Tibben, Yaogeng Wang, Maria C Lebre, Hilde Rosing, Jos H Beijnen, Alfred H Schinkel
P-glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF-β signaling pathway inhibitor galunisertib. International journal of cancer 146 (6) (2019)
Alejandra Martínez-Chávez, Stéphanie van Hoppe, Hilde Rosing, Maria C Lebre, Matthijs Tibben, Jos H Beijnen, Alfred H Schinkel
P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. Molecular pharmaceutics 16 (9) (2019)
Wenlong Li, Rolf W Sparidans, Yaogeng Wang, Maria C Lebre, Els Wagenaar, Jos H Beijnen, Alfred H Schinkel
P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International journal of cancer 143 (8) (2018)